A study of second-line irinotecan plus cisplatin vs. irinotecan alone in platinum-naïve patients with early relapse of gastric cancer refractory to adjuvant S-1 monotherapy: exploratory subgroup analysis of the randomized phase III TRICS trial.
Nishikawa K, Murotani K, Fujitani K, Inagaki H, Akamaru Y, Tokunaga S, Takagi M, Tamura S, Sugimoto N, Shigematsu T, Yoshikawa T, Ishiguro T, Nakamura M, Hasegawa H, Morita S, Miyashita Y, Tsuburaya A, Sakamoto J, Tsujinaka T.
Nishikawa K, et al. Among authors: inagaki h.
Cancer Chemother Pharmacol. 2019 May;83(5):867-874. doi: 10.1007/s00280-019-03802-9. Epub 2019 Feb 26.
Cancer Chemother Pharmacol. 2019.
PMID: 30806758
Clinical Trial.